Question 1

What specific benefits do you think ALK-001 could offer me compared to my current treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) clinical trial (NCT04239625). Contact the study team or your healthcare provider for specific answers.

Question 2

Are there any potential side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) clinical trial (NCT04239625). Contact the study team or your healthcare provider for specific answers.

Question 3

How often will I need to visit the study site, and what will those visits involve?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) clinical trial (NCT04239625). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I experience side effects during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) clinical trial (NCT04239625). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my progress be monitored throughout the 24 months?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) clinical trial (NCT04239625). Contact the study team or your healthcare provider for specific answers.

Question 6

Is there any cost associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) clinical trial (NCT04239625). Contact the study team or your healthcare provider for specific answers.

What this study is about